Stocky turns companies like AUPH into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Buy. Aurinia's 96/100 Growth Compounder Score reflects LUPKYNIS's strong lupus nephritis uptake driving 40%+ revenue growth, while leadership's founder-CEO ownership and 7.2× margin of safety provide downside protection. Chief vulnerability: sole-source manufacturing for API and drug product creates supply chain risk that could disrupt commercialization momentum.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for AUPH:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 79/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates AUPH (AUPH) at 79/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Buy. Aurinia's 96/100 Growth Compounder Score reflects LUPKYNIS's strong lupus nephritis uptake driving 40%+ revenue growth, while leadership's founder-CEO ownership and 7.2× margin of safety provide downside protection. Chief v
AUPH's current Stocky Verdict is 79/100, placing it in the "Buy" band. This composite combines a 96/100 Compounder score, 74/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for AUPH yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
AUPH scores 74/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
AUPH's Vulnerability Profile scores 75/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to AUPH.
Sign up free and unlock the full analysis on AUPH — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for AUPH in the app.
